On August 31, 2023 Genor Biopharma reported its interim results for 2023, sharing the company’s business progress, financial data, highlights during the period, and future development prospects (Presentation, Genor Biopharma, AUG 31, 2023, View Source [SID1234635019]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. GUO Feng, Chairman of the Board and Chief Executive Officer, Genor Biopharma, said: "With the continuous implementation of the ‘Focus, Optimization, Acceleration, Expansion’ strategy, Genor Biopharma successfully continued to rapidly promote the existing pipeline in the first half of 2023. One of our core products garnered international recognition at industry academic conferences. Furthermore, the results of the early research platform and the pressing on with commercial cooperation laid a solid foundation for the long-term sustainable development of the company."